https://www.selleckchem.com/pr....oducts/atezolizumab.
Monobodies are synthetic non-immunoglobulin customizable protein binders invaluable to basic and applied research, and of considerable potential as future therapeutics and diagnostic tools. The ability to reversibly control their binding activity to their targets on demand would significantly expand their applications in biotechnology, medicine, and research. Here we present, as proof-of-principle, the development of a light-controlled monobody (OptoM that works in vitro and in cells and whose affinity for its SH2-domain target e
Like
Comment
Share
